Antithrombin Enhancement May Improve Anticoagulation Efficiency in Infants Undergoing Cardiopulmonary Bypass for Cardiac Surgery

The Hospital for Sick Children18 enrolled

Overview

The primary objective of this study is: 1\. To evaluate the use of Antithrombin (AT) concentrate in infants less than one year of age undergoing cardiopulmonary bypass (CPB) for cardiac surgery The secondary objectives of this study are: 1. To determine if the administration of AT concentrate prior to heparinization will decrease the amount of heparin required to achieve optimal anticoagulation (as defined by anti-Xa levels) during CPB 2. To determine if a decrease in activation and consumption of coagulation proteins, platelets and subsequent fibrinolysis will result in improved haemostasis following CPB 3. To determine if there will be a reduction in postoperative bleeding and associated clinical complications

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Cardiopulmonary Bypass

Interventions

Saline PlaceboOTHER

Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.

Eligibility

Sex: ALLMax age: 364 Days

Medical Language ↔ Plain English

Inclusion Criteria: 1. Pediatric patients \< 1 year old with cardiac defect (acquired or congenital) requiring cardiac surgery 2. Planned cardiac surgery with cardiopulmonary bypass 3. Weight \> 2.5kg at the time of surgery 4. Enrolment in the CATCH main study (REB#1000020203) Exclusion Criteria: 1. Preoperative antithrombin activity \> 85% 2. Prematurity \< 36 weeks gestational age at birth 3. Preoperative use of systemic anticoagulant (i.e. heparin or warfarin at a therapeutic dose) for \> 24 hours or at any time within the 48 hours prior to surgery 4. Any form of coagulopathy or thrombophilic disorder 5. Renal (blood creatinine - estimated GRF \< 60ml/min/1.73m2) or clinical liver failure 6. Antithrombin replacement therapy prior to surgery 7. Repeat surgery (including previous ECMO/VAD support as prior surgery) 8. Patients refusal to provide open consent for re-use of study data

Outcomes

Primary Outcomes

Chest tube volume loss

Chest tube volume loss (mls/kg) at 24 hours in CCCU

Time frame: 24 hrs post surgery

Secondary Outcomes

Heparin dose required to achieve target Activated Clotting Time required to go on Cardiopulmonary Bypass

Clinical Outcome Measure

Time frame: 1hr prior to induction of anaestheisa (pre-surgery)

Blood product transfusions intra-operatively and for the first 24 hours following surgery

Time frame: 24hours post surgery

Clinical outcomes

(inotropic support, ventilation, CCU stay, hospital stay, thrombosis)

Time frame: 30 days post-surgery

Intraoperative coagulation profile

(anti-Xa, heparin concentration, activated clotting time, CBC, antithrombin)

Time frame: 5 hours after start of surgery

Post-operative markers of platelet activation

Post-operative markers of platelet activation (TAT, F1.2), fibrinolysis (d-dimer) and inflammation (CRP)

Time frame: 24 and 72 hrs post surgery

Use of recombinant factor VIIa after surgery to control post-operative bleeding

Time frame: 48 hrs post surgery